RP01915

Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Recombinant Human IFN-alpha G/IFNA5 Protein

Catalog No.: RP01915 Recombinant

Sequence Information

Species	Gene ID	Swiss Prot
HEK293 cells	3442	P01569

Tags
C-His

Synonyms
Ifa5; IFNA5; IFNalpha G; IFN-alpha G; IFN-alpha-5; IFN-alphaG; INFA5; interferon alpha-5; Interferon alpha-61; Interferon alpha-G; interferon; alpha 5; LeIF G

Product Information

Source
HEK293 cells

Purification
≥ 90% as determined by SDS-PAGE.

Endotoxin
< 0.1 EU/μg of the protein by LAL method.

Formulation
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

Reconstitution
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Contact

www.abclonal.com

Background

Interferon, alpha 5 (IFNA5) belongs to the alpha/beta interferon family. IFNA5 is the only IFNA subtype detected in normal liver, while a mixture of subtypes is observed in the liver tissue of patients with chronic hepatitis C. Interferons are produced by macrophages, IFN-alpha has antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of growth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. Originally discovered as an antiviral substance, the efficacy of IFN-alpha in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. IFN-alpha emerged as a prototypic tumor suppressor protein that represses the clinical tumorigenic phenotype in some malignancies capable of differentiation.

Basic Information

Description
Recombinant Human interferon-alpha/IFNA5 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Leu22-Glu189) of Human interferon-alpha/IFNA5 (Accession #NP_002160.1) fused with a His tag at the C-terminus.

Bio-Activity
Measured in a cell cytotoxicity assay using TF-1 cells. The ED_{50} for this effect is 3.27□ 13.06 ng/mL, corresponding to a specific activity of 7.66×10^{4}-3.06×10^{5} units/mg.

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Operational Notes
For your safety and health, please wear a lab coat and disposable gloves for handling.

Storage
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
Avoid repeated freeze/thaw cycles.

* For your safety and health, please wear a lab coat and disposable gloves when handling.

Validation Data



Recombinant Human IFN-alpha G/IFNA5 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.



Recombinant Human IFN-alpha G/IFNA5 was measured in a cell cytotoxicity assay using TF-1 cells. The ED_{50} for this effect is 3.27□ 13.06 ng/mL, corresponding to a specific activity of 7.66×10^{4}~3.06×10^{5} units/mg.